According to OpenAI and Greg Brockman on X, OpenAI has acquired Orchestra Bio to integrate its coordination platform with Rosalind AI tools, aiming to streamline biopharma drug development operations and speed treatments to patients.

According to OpenAI, the company acquired Orchestra Bio to integrate its coordination platform with Rosalind AI models and tools to streamline biopharma R&D operations.

According to sama, OpenAI launched Rosalind to harden biodefense with guardrails, evaluations, and partnerships for safer bio research.